# A Phase II Trial of Sofosbuvir (SOF) and GS-5816 for People With Chronic Hepatitis C Virus Infection and Recent Injection Drug Use

> **NCT02336139** · PHASE2 · COMPLETED · sponsor: **Kirby Institute** · enrollment: 103 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** Sofosbuvir (SOF)/GS-5816

## Key facts

- **NCT ID:** NCT02336139
- **Lead sponsor:** Kirby Institute
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-16
- **Primary completion:** 2017-04-17
- **Final completion:** 2018-11-28
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2019-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02336139

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02336139, "A Phase II Trial of Sofosbuvir (SOF) and GS-5816 for People With Chronic Hepatitis C Virus Infection and Recent Injection Drug Use". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02336139. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*